Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST) - PubMed (original) (raw)
Clinical Trial
. 2002 Feb 20;39(4):610-6.
doi: 10.1016/s0735-1097(01)01783-1.
Affiliations
- PMID: 11849859
- DOI: 10.1016/s0735-1097(01)01783-1
Free article
Clinical Trial
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST)
Yasunori Sawayama et al. J Am Coll Cardiol. 2002.
Free article
Abstract
Objectives: This study investigated the effect of reducing serum lipids on carotid artery intima-media thickness (IMT) in asymptomatic patients with hypercholesterolemia from Fukuoka, Japan.
Background: Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in patients with coronary heart disease (CHD).
Methods: A total of 246 asymptomatic hypercholesterolemic patients (mean age 66 years) were randomized to receive either probucol (500 mg/day, n = 82) or pravastatin (10 mg/day, n = 83) or to enter a control group (diet alone, n = 81); they were followed for two years. The change in IMT in the common carotid artery was the primary end point measure, and the incidence of major cardiovascular events was the secondary measure.
Results: Over the two-year period, serum low-density lipoprotein (LDL) cholesterol was significantly reduced in the pravastatin group (36%), the probucol group (29%) and the control group (12%) (p < 0.0001, p < 0.0001 and p < 0.05, respectively). After two years, the probucol and pravastatin groups showed a significant reduction in IMT (-13.9% and -13.9% and p < 0.01 and p < 0.01, respectively), but there was significant IMT thickening (23.2%; p < 0.05) in the control group. Probucol reduced the rate of IMT increase, independently of its reduction of LDL or high-density lipoprotein cholesterol. Moreover, there was a significantly lower incidence of cardiac events in the probucol group (2.4%) than in the control group (13.6%) (p = 0.0136).
Conclusions: Probucol reduced cholesterol levels and stabilized plaque, leading to a lower incidence of cardiac events in these hypercholesterolemic patients.
Similar articles
- Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
Sawayama Y, Maeda S, Ohnishi H, Okada K, Hayashi J. Sawayama Y, et al. Fukuoka Igaku Zasshi. 2006 Jan;97(1):15-24. Fukuoka Igaku Zasshi. 2006. PMID: 16613215 Clinical Trial. - Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Salonen R, et al. Circulation. 1995 Oct 1;92(7):1758-64. doi: 10.1161/01.cir.92.7.1758. Circulation. 1995. PMID: 7671358 Clinical Trial. - Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study.
Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alò G, Ventura A. Mercuri M, et al. Am J Med. 1996 Dec;101(6):627-34. doi: 10.1016/s0002-9343(96)00333-6. Am J Med. 1996. PMID: 9003110 Clinical Trial. - The "null effect" of low-density lipoprotein cholesterol lowering on a modest baseline intima-media thickness: lessons learned from the ENHANCE trial.
Franklin BA, McCullough PA. Franklin BA, et al. Prev Cardiol. 2008 Summer;11(3):177-8. doi: 10.1111/j.1751-7141.2008.08624.x. Prev Cardiol. 2008. PMID: 18607155 Review. No abstract available. - Surrogate markers of atherosclerosis: impact of statins.
Kastelein JJ, Wiegman A, de Groot E. Kastelein JJ, et al. Atheroscler Suppl. 2003 Mar;4(1):31-6. doi: 10.1016/s1567-5688(03)00007-2. Atheroscler Suppl. 2003. PMID: 12714035 Review.
Cited by
- Pharmacological interventions for asymptomatic carotid stenosis.
Clezar CN, Flumignan CD, Cassola N, Nakano LC, Trevisani VF, Flumignan RL. Clezar CN, et al. Cochrane Database Syst Rev. 2023 Aug 4;8(8):CD013573. doi: 10.1002/14651858.CD013573.pub2. Cochrane Database Syst Rev. 2023. PMID: 37565307 Free PMC article. Review. - Safety and efficacy of low-dose rt-PA with tirofiban to treat acute non-cardiogenic stroke: a single-center randomized controlled study.
Liang Z, Zhang J, Huang S, Yang S, Xu L, Xiang W, Zhang M. Liang Z, et al. BMC Neurol. 2022 Jul 27;22(1):280. doi: 10.1186/s12883-022-02808-w. BMC Neurol. 2022. PMID: 35897006 Free PMC article. Clinical Trial. - Non-Transferrin-Bound Iron in the Spotlight: Novel Mechanistic Insights into the Vasculotoxic and Atherosclerotic Effect of Iron.
Vinchi F. Vinchi F. Antioxid Redox Signal. 2021 Aug 20;35(6):387-414. doi: 10.1089/ars.2020.8167. Epub 2021 Mar 22. Antioxid Redox Signal. 2021. PMID: 33554718 Free PMC article. Review. - All-Cause Mortality and Cardiovascular Death between Statins and Omega-3 Supplementation: A Meta-Analysis and Network Meta-Analysis from 55 Randomized Controlled Trials.
Kim J, Hoang T, Kim JM, Bu SY, Choi JH, Park E, Lee SM, Park E, Min JY, Lee IS, Youn SY, Yeon JY. Kim J, et al. Nutrients. 2020 Oct 20;12(10):3203. doi: 10.3390/nu12103203. Nutrients. 2020. PMID: 33092130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical